A Phase II Study of the Hsp90 Inhibitor, STA-9090, in Patients With Relapsed or Refractory Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2017
At a glance
- Drugs Ganetespib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 28 Feb 2017 Status changed from active, no longer recruiting to completed.
- 25 Feb 2013 Planned End Date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 25 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.